Continued Low Efficacy of Artemether-Lumefantrine in Angola?
作者信息
Rasmussen Charlotte, Ringwald Pascal
机构信息
Global Malaria Programme, World Health Organization, Geneva, Switzerland
Global Malaria Programme, World Health Organization, Geneva, Switzerland.
出版信息
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00220-21.
Abstract
摘要
相似文献
1
Continued Low Efficacy of Artemether-Lumefantrine in Angola?蒿甲醚-本芴醇在安哥拉的疗效持续低下？
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00220-21.
2
Reply to Rasmussen and Ringwald, "Continued Low Efficacy of Artemether-Lumefantrine in Angola?".对拉斯穆森和林瓦尔德《蒿甲醚-本芴醇在安哥拉持续低效？》的回复
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00338-21.
3
Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017.2017 年在安哥拉三省用青蒿琥酯-本芴醇、青蒿琥酯-阿莫地喹和双氢青蒿素-哌喹治疗无并发症恶性疟原虫疟疾的疗效和安全性。
Malar J. 2018 Apr 3;17(1):144. doi: 10.1186/s12936-018-2290-9.
4
Artemether-lumefantrine treatment failure of uncomplicated Plasmodium falciparum malaria in travellers coming from Angola and Mozambique.来自安哥拉和莫桑比克的旅行者中非复杂性间日疟原虫疟疾病人青蒿琥酯-咯萘啶治疗失败。
Int J Infect Dis. 2021 Sep;110:151-154. doi: 10.1016/j.ijid.2021.07.008. Epub 2021 Jul 7.
5
Continued Low Efficacy of Artemether-Lumefantrine in Angola in 2019.2019 年安哥拉青蒿琥酯-咯萘啶的疗效持续不佳。
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.01949-20.
6
Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola.蒿甲醚-本芴醇和双氢青蒿素-哌喹治疗安哥拉扎伊尔省和威热省儿童非复杂性疟疾的疗效
Antimicrob Agents Chemother. 2015 Jan;59(1):437-43. doi: 10.1128/AAC.04181-14. Epub 2014 Nov 3.
7
Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015.2015 年安哥拉三省无并发症恶性疟原虫感染患者中青蒿素和咯萘啶耐药相关分子标志物的流行情况。
Malar J. 2018 Feb 20;17(1):84. doi: 10.1186/s12936-018-2233-5.
8
Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015.2015年，蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹及双氢青蒿素-哌喹治疗安哥拉非复杂性恶性疟的疗效
Malar J. 2017 Feb 2;16(1):62. doi: 10.1186/s12936-017-1712-4.
9
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.三药联合疗法与青蒿素类复方疗法治疗无并发症恶性疟原虫疟疾的比较：一项多中心、开放标签、随机临床试验。
Lancet. 2020 Apr 25;395(10233):1345-1360. doi: 10.1016/S0140-6736(20)30552-3. Epub 2020 Mar 11.
10
A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa.一项在非洲针对无并发症恶性疟原虫感染妊娠妇女的青蒿琥酯- 双氢青蒿素三日和五日疗程的随机对照试验。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01140-19.
引用本文的文献
1
Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa.撒哈拉以南非洲疟疾感染人群中恶性疟原虫K13基因对青蒿素联合疗法及相关药物的新出现突变
Parasites Hosts Dis. 2025 May;63(2):109-122. doi: 10.3347/PHD.24053. Epub 2025 May 26.
2
drug susceptibility and resistance mediating genetic polymorphisms of in Bobo-Dioulasso, Burkina Faso.博博迪乌拉索（布基纳法索）中 耐药和敏感性相关的遗传多态性
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0153423. doi: 10.1128/aac.01534-23. Epub 2024 Feb 27.
3
Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa.非洲青蒿素部分耐药疟原虫的出现、传播动态和机制。
Nat Rev Microbiol. 2024 Jun;22(6):373-384. doi: 10.1038/s41579-024-01008-2. Epub 2024 Feb 6.
4
A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria.在非洲采用新抗疟药物的利益相关者参与框架：以尼日利亚为例的案例研究。
Malar J. 2023 Jun 17;22(1):185. doi: 10.1186/s12936-023-04622-2.
5
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders' perspectives in Burkina Faso and Nigeria.在布基纳法索和尼日利亚部署三药联合疗法治疗疟疾的伦理考虑：利益攸关方观点分析。
PLoS One. 2022 Sep 9;17(9):e0273249. doi: 10.1371/journal.pone.0273249. eCollection 2022.
6
Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook.恶性疟原虫对青蒿素类复方药物的抗药性：出现、机制和展望。
Int J Parasitol Drugs Drug Resist. 2021 Aug;16:102-118. doi: 10.1016/j.ijpddr.2021.05.007. Epub 2021 May 26.
7
Reply to Rasmussen and Ringwald, "Continued Low Efficacy of Artemether-Lumefantrine in Angola?".对拉斯穆森和林瓦尔德《蒿甲醚-本芴醇在安哥拉持续低效？》的回复
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00338-21.
本文引用的文献
1
Continued Low Efficacy of Artemether-Lumefantrine in Angola in 2019.2019 年安哥拉青蒿琥酯-咯萘啶的疗效持续不佳。
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.01949-20.
2
A Computer Modelling Approach To Evaluate the Accuracy of Microsatellite Markers for Classification of Recurrent Infections during Routine Monitoring of Antimalarial Drug Efficacy.一种计算机建模方法，用于评估微卫星标记在常规抗疟药物疗效监测中对复发性感染分类的准确性。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01517-19.
3
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.蒿甲醚-本芴醇治疗非复杂性恶性疟：一项使用个体患者数据对第7天本芴醇浓度和治疗反应进行的系统评价和荟萃分析。
BMC Med. 2015 Sep 18;13:227. doi: 10.1186/s12916-015-0456-7.
4
Robust Algorithm for Systematic Classification of Malaria Late Treatment Failures as Recrudescence or Reinfection Using Microsatellite Genotyping.使用微卫星基因分型将疟疾晚期治疗失败系统分类为复发或再感染的稳健算法
Antimicrob Agents Chemother. 2015 Oct;59(10):6096-100. doi: 10.1128/AAC.00072-15. Epub 2015 Jul 20.
5
Evidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to artemether.苏里南第3日疟原虫血症发病率增加的证据：恶性疟原虫对蒿甲醚出现耐药性的一个指标。
Mem Inst Oswaldo Cruz. 2013 Dec;108(8):968-73. doi: 10.1590/0074-0276130167.
Zotero 插件